-
Mashup Score: 2CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma | NEJM - 7 hour(s) ago
We describe two patients in whom malignant monoclonal T-cell lymphoproliferation developed after administration of chimeric antigen receptor (CAR) T-cell therapy with ciltacabtagene autoleucel (cil…
Source: www.nejm.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0Saudia | Book flights | Hotels | Holidays - 1 month(s) ago
You can find the 6-character Booking Reference, or the 13-digit E-ticket Number in the confirmation
Source: www.saudia.comCategories: General Medicine News, CardiologistsTweet-
L My p https://t.co/bfP5nzBsfw
-
-
Mashup Score: 0CAR-T cell therapies for T cell malignancies: does cellular immunotherapy represent the best chance of cure? - 2 month(s) ago
Chimeric antigen receptor T cell (CAR-T) therapy has proven successful for B cell lymphomas and leukaemias. This success has inspired the development of CA
Source: ashpublications.orgCategories: General Medicine News, CardiologistsTweet-
CAR-T for T cell malignancies: the future is bright! šš¾šš¾ #lymsm #CART https://t.co/LP5iKukIVq
-
-
Mashup Score: 5
Program: Oral and Poster Abstracts Type: Oral Session: 623. Mantle Cell, Follicular, Waldenstromās, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Clinical Trials for Marginal Zone Lymphoma, Waldenstrom’s Macroglobulinemia and Hairy Cell Leukemia Hematology Disease Topics & Pathways: Research, Clinical trials, Lymphomas, Non-Hodgkin lymphoma, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Indolent lymphoma, Treatment Considerations, Biological therapies,
Source: ash.confex.comCategories: General Medicine News, CardiologistsTweet-
5-yr Fu of Zuma-5 (axi-cel in iNHL) Med fu 64.6 mo Med DOR 60.4 mo Med PFS 62.2 mo Med OS NR 60-mo OS est 69.0% Among pts with CR, 58% remained in CR!šš¾ Higher med post-infusion peak CAR T-cell expansion in pts with ongoing response #ASH24 #lymsm https://t.co/FqNarYqrS7
-
-
Mashup Score: 2ViPORās Venom ā Rationally Targeting DLBCL with Precision | NEJM - 8 month(s) ago
Large B-cell lymphoma (LBCL) spans the gamut of aggressive lymphoid tumors with extensive biologic and clinical heterogeneity. Most patients with LBCL are cured with the use of front-line chemoimmu…
Source: www.nejm.orgCategories: General Medicine News, CardiologistsTweet-
Elegant editorial by Drs Goldstein & @AshAlizadeh #lymsm https://t.co/ZH6pqzODsg
-
-
Mashup Score: 5
The identification of oncogenic mutations in diffuse large B-cell lymphoma (DLBCL) has led to the development of drugs that target essential survival pathways, but whether targeting multiple surviv…
Source: www.nejm.orgCategories: General Medicine News, CardiologistsTweet-
ViPOR for r/r DLBCL (med 3 lines of prior Rx) ORR 54%, CR 38% (exclusively in pts with non-GCB DLBCL & HGBL) undetectable ctDNA in 33% at EOT 2-yr PFS 34%, 2-yr OS 36% PFS for ViPOR as 2L>3L/later Prior CART: ORR 45%, CR 20%, 2-yr PFS 30%!!, 2-yr OS 30%!! https://t.co/2ZCJLIqvYc
-
-
Mashup Score: 4A major role for CD4+ TĀ cells in driving cytokine release syndrome during CAR TĀ cell therapy - 2 year(s) ago
Boulch etĀ al. report that CD4+ CAR TĀ cells play a more important role than their CD8+ counterparts in triggering cytokine release syndrome, a life-threatening complication of CAR TĀ cell therapy. Fine-tuning of the CD4:CD8 CAR TĀ cell ratio may therefore help mitigate CAR TĀ cell-associated toxicities.
Source: www.cell.comCategories: Cardiologists, Latest HeadlinesTweet-
RT @MaxMamonkin: CD4+ CART are a driver of CRS in high tumor burden scenarios. https://t.co/LbamddCMnH
-
-
Mashup Score: 15
The FDA approved Lantidra, the first cellular therapy for the treatment of adults with type 1 diabetes.
Categories: Cardiologists, Latest HeadlinesTweet-
RT @FDAMedia: FDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes https://t.co/tR3GgKnbbu
-
-
Mashup Score: 0Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma - 2 year(s) ago
Key Points. Mosunetuzumab is active as a single agent and yields complete responses in 24% of heavily pretreated patients with R/R DLBCL.Step-up dosing mitigate
Source: American Society of HematologyCategories: Cardiologists, Latest HeadlinesTweet-
Mosunetuzumab in r/r DLBCL 88pts (DLBCL 74%, tFL 26%) CR 24%, ORR 42%, medianTTR 1.4mo, mDOR 7mo, medianTT CR 3mo mPFS 3.2mo, mOS 11.5mo Prior CAR-T: 26/88 w CR 12% CRS 26% (mainly Gr 1-2) Small n w bulky dx...#lymsm Kudos to @nancybartlettMD & team https://t.co/FnO96QnxyI
-
-
Mashup Score: 55-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1) - 2 year(s) ago
Key Points. Axicabtagene ciloleucel induced long-term survival with no new safety signals in patients with refractory large B-cell lymphomaDurable responses wer
Source: American Society of HematologyCategories: Cardiologists, Latest HeadlinesTweet-
5yr FU Supports Curative Potential of Axi-Cel in R/R LBCL (ZUMA-1) Median FU of 63.1 mo Median EFS - 5.7 mo 5yr EFS - 30.3% Ongoing response in 31% of pts Median OS - 25.8 mo 5-year OS - 42.6% Early CAR T-cell expansion associated with ongoing response https://t.co/ZYcXpF2Zj8
-
CAR T-cell associated-PTCL after CAR T-cell for relapsed or refractory myeloma https://t.co/mwrQ3eQxC5